Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAC457)

• Drug Name: LY3127804 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

• Therapeutic Class: Antiviral Agents
• Cross-matching ID: TTD Drug ID: DMAC457

Molecule-Related Drug Atlas

Drug(s) Targeting Angiopoietin-2 (ANGPT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Faricimab	DM83SEB	Diabetic macular edema	9B71.02	Approved	[4]
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[5]
Trebananib	DMOG2X1	Ovarian cancer	2C73	Phase 3	[6]
RG7221	DM8J9DC	Colorectal cancer	2B91.Z	Phase 2	[7]
RO5520985	DMD3WNP	Colorectal cancer	2B91.Z	Phase 2	[8]
REGN910-3	DMTBRPO	Neovascular age-related macular degeneration	9B78.3Z	Phase 2	[9]
CVX-060	DM03LWZ	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[10]
BI 836880	DMRI6YT	Neoplasm	2A00-2F9Z	Phase 1	[11]
CVX-241	DMV74JC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
REGN-910	DMHR7D4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HUMAN angiopoietin-2 (ANG-2)	TT0APVH	ANGP2_HUMAN	Inhibitor	[3]
Angiopoietin-2 (ANGPT2)	TTKLQTJ	ANGP2_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT04342897) A Study of LY3127804 in Participants With COVID-19. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Updates: Lilly's Global COVID-19 Response
• [4] Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
• [5] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [6] Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069.
• [7] Company report (Roche pipeline: July 27, 2017)
• [8] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [9] ClinicalTrials.gov (NCT02713204) Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX). U.S. National Institutes of Health.
• [10] Clinical pipeline report, company report or official report of CovX (2011).
• [11] Clinical pipeline report, company report or official report of Boehringer Ingelheim.
• [12] Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A. 2010 December 28; 107(52): 22611-22616.
• [13] Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013 Jan 1;73(1):108-18.